Tan Jie, Zhang Chenxia, Qian Jianzhong
Department of Gynaecology, Jiangyin Hospital, Medical School of Southeast of China University, No. 35 East of Renming Road, Jiangyin, 214400, China.
Tumour Biol. 2011 Dec;32(6):1241-7. doi: 10.1007/s13277-011-0228-8. Epub 2011 Aug 27.
This study aimed to investigate the expression of Six1 gene and its downstream target gene Ezrin in cervical cancer, and to correlate their expression to the clinical pathology of cervical cancer. RT-PCR and Western blot were used to detect the expression of Six1 and Ezrin in cervical cancer tissue, cervical intraepithelial neoplasia tissue, and normal cervical tissue. The correlation of Six1 and Ezrin expression with the occurrence, development, and clinical pathology of cervical cancer was then analyzed. The expression of Six1 and Ezrin mRNA and protein in cervical cancer and cervical intraepithelial neoplasia was significantly higher than in normal cervical tissue (p < 0.05). Their expression was also significantly higher in the cancerous tissues of patients with advanced cervical cancer than in those of patients with early-stage cervical cancer (p < 0.05). Moreover, they were expressed at significantly higher levels in lymph node metastasis-positive patients than in lymph node metastasis-negative patients (p < 0.05). Finally, we observed that lesser differentiated tumors had elevated expression of Six1 and Ezrin mRNA and protein (p < 0.05). However, the mRNA and protein expression of Six1 and Ezrin were independent of patient age and tumor size (p > 0.05). Further investigation is warranted to describe the relation of whether Six1 and Ezrin protein contributes to the mechanism of occurrence, development, differentiation, and invasiveness of the tumor. These markers could be used as indicators of prognosis in early-stage cervical cancer as Six1 and Ezrin had a synergistic effect on the incidence of cervical cancer.
本研究旨在探讨Six1基因及其下游靶基因埃兹蛋白（Ezrin）在宫颈癌中的表达情况，并将它们的表达与宫颈癌的临床病理特征相关联。采用逆转录聚合酶链反应（RT-PCR）和蛋白质免疫印迹法（Western blot）检测Six1和Ezrin在宫颈癌组织、宫颈上皮内瘤变组织及正常宫颈组织中的表达。然后分析Six1和Ezrin表达与宫颈癌发生、发展及临床病理特征的相关性。Six1和Ezrin的信使核糖核酸（mRNA）及蛋白在宫颈癌和宫颈上皮内瘤变中的表达显著高于正常宫颈组织（p < 0.05）。它们在晚期宫颈癌患者癌组织中的表达也显著高于早期宫颈癌患者（p < 0.05）。此外，它们在淋巴结转移阳性患者中的表达水平显著高于淋巴结转移阴性患者（p < 0.05）。最后，我们观察到低分化肿瘤中Six1和Ezrin的mRNA及蛋白表达升高（p < 0.05）。然而，Six1和Ezrin的mRNA及蛋白表达与患者年龄和肿瘤大小无关（p > 0.05）。有必要进一步研究Six1和Ezrin蛋白是否与肿瘤的发生、发展、分化及侵袭机制有关。由于Six1和Ezrin对宫颈癌的发生有协同作用，这些标志物可作为早期宫颈癌预后的指标。
